A Multicenter, Phase I, Open-label, Uncontrolled Study of ONO-4059 in Combination With Rituximab, Methotrexate, Procarbazine, and Vincristine (R-MPV) Therapy for Untreated Primary Central Nervous System Lymphoma (PCNSL)
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Tirabrutinib (Primary) ; Methotrexate; Procarbazine; Rituximab; Vincristine
- Indications CNS cancer; Lymphoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 03 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 12 Aug 2024 New trial record